Remove Drug Development Remove Drug Pricing Remove Pharmaceutical Companies
article thumbnail

STAT+: Gilead plans to halt free access to an HIV drug, worrying patient advocates

STAT

Access to cheaper alternatives and low enrollment prompted the company to remove the medicine — along with the HIV medicines Emtriva, Tybost, and Complera — from its patent assistance program next month, according to an Oct. 8 letter that announced the move and that has not been widely reported.

article thumbnail

Effective Drug Patent Prosecution Strategies: Securing Your Pharmaceutical Innovations

Drug Patent Watch

This exclusivity is the lifeblood of pharmaceutical innovation, allowing companies to recoup their massive R&D investments and incentivizing further research. According to a 2021 study by the Tufts Center for the Study of Drug Development, the average cost to develop a new drug is a staggering $2.6

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Navigating the IPR maze: India’s pharmaceutical challenge

Express Pharma

On one hand, robust IPR protection is essential to incentivise research and development. It encourages pharmaceutical companies to invest heavily in discovering new drugs, developing innovative treatments, and improving healthcare outcomes. However, the flip side of the coin is equally important.

article thumbnail

RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals

Pharmaceutical Technology

wants to ensure the ensuing the US does not lag behind other countries in drug development. We want to make sure we are getting rid of the regulatory impediments [that stop drugs getting to market],” RFK Jr stated. “It Tasos Katopodis / Stringer via Getty Images.

article thumbnail

The Brazilian pharma market: Key information and what may change

Pharmaceutical Technology

Despite this, Brazil’s trade protectionist policies mean that there are few pharmaceutical companies of international origin within the country. There are also strict price controls, which in some cases can limit profitability for manufacturers. Brazilian public spending on healthcare, drug pricing reforms and remote medicine.

article thumbnail

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Pharmaceutical Technology

Almost 40 years since it was instituted, some have described the FDA’s orphan drug program, which is meant to foster innovation, as “ one of the most successful US legislative actions in recent history ”. However, extended market exclusivity is often associated with high drug pricing and limited patient access.

article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

What’s more, with many key biologics scheduled to lose patent protection in this decade, Indian pharmaceutical companies ought to seize this opportunity and leverage innovative technologies to introduce quality and way more affordable biosimilars in the domestic as well as global markets. appeared first on Express Pharma.